Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 7/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16417897 | 1.00 | HDAC6 (0.67) | HDAC6CCNT1CDK9MEN1PABPC1 | |
| SCHEMBL16417896 | 1.00 | HDAC6 (0.67) | HDAC6CCNT1CDK9MEN1PABPC1 | |
| SCHEMBL16417901 | 1.00 | HDAC6 (0.67) | HDAC6CCNT1CDK9MEN1PABPC1 | |
| SCHEMBL13641216 | 1.00 | HDAC6 (0.67) | HDAC6CCNT1CDK9MEN1PABPC1 | |
| SCHEMBL16417900 | 1.00 | HDAC6 (0.67) | HDAC6CCNT1CDK9MEN1PABPC1 | |
| SCHEMBL13641116 | 1.00 | HDAC6 (0.67) | HDAC6CCNT1CDK9MEN1PABPC1 | |
| SCHEMBL13641215 | 1.00 | HDAC6 (0.67) | HDAC6CCNT1CDK9MEN1PABPC1 | |
| SCHEMBL16417898 | 1.00 | HDAC6 (0.67) | HDAC6CCNT1CDK9MEN1PABPC1 | |
| SCHEMBL13640289 | 1.00 | HDAC6 (0.67) | HDAC6CCNT1CDK9MEN1PABPC1 | |
| SCHEMBL6951852 | 1.00 | HDAC6 (0.67) | HDAC6CCNT1CDK9MEN1PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0994890-B1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2003-08-06 | — | — | EP | claimed |
| US-6455507-B1 | E.G., 2-BROMO-5,6-DICHLORO-1-BETA-D-RIBOPYRANOSYL-1H-BENZIMIDAZOLE; VIRICIDES, ESPECIALLY INFECTIONS OF HERPES AND CYTOMEGALO VIRUSES | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | claimed |
| EP-0994890-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-04-26 | — | — | EP | claimed |
| WO-1998056761-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-12-17 | — | — | WO | claimed |
| US-20170027974-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | SHIRE VIROPHARMA LLC | 2017-02-02 | — | — | US | disclosed |
| US-20160175338-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | VIROPHARMA INCORPORATED | 2016-06-23 | — | — | US | disclosed |
| US-8940707-B2 | Maribavir isomers, compositions, methods of making and methods of using | VIROPHARMA INCORPORATED (US) | 2015-01-27 | — | — | US | disclosed |
| US-20120283210-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | SHIRE VIROPHARMA LLC | 2012-11-08 | — | — | US | disclosed |
| EP-0994890-B1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-6455507-B1 | E.G., 2-BROMO-5,6-DICHLORO-1-BETA-D-RIBOPYRANOSYL-1H-BENZIMIDAZOLE; VIRICIDES, ESPECIALLY INFECTIONS OF HERPES AND CYTOMEGALO VIRUSES | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
| US-20020094963-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO WELLCOME INC. | 2002-07-18 | — | — | US | disclosed |
| EP-0994890-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998056761-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283210-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885CCNT1 357/4885CDK9 223/4885 |
| US-20160175338-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885CCNT1 357/4885CDK9 223/4885 |
| US-20020094963-A1 | BENZIMIDAZOLE DERIVATIVES | ZC3HAV1, BRPF3, BRD3 | HDAC6 44/4885CCNT1 483/4885CDK9 138/4885 |
| US-20170027974-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885CCNT1 357/4885CDK9 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.